NYSEAMERICAN:VTAK

Catheter Precision Q3 2025 Earnings Results & Report

Catheter Precision logo
$0.15 0.00 (0.00%)
As of 10/9/2026

Catheter Precision beat analyst earnings expectations but missed on revenue in its Q3 2025 results, released November 13, 2025. The company reported EPS of -$17.00 versus the -$266.00 consensus estimate, while revenue of $226 thousand fell short of the $1.20 million estimate by $974 thousand.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens

Catheter Precision EPS Results

Actual EPS
-$17.00
Consensus EPS
-$266.00
Beat/Miss
Beat by +$249.00
One Year Ago EPS
N/A

Catheter Precision Revenue Results

Actual Revenue
$226 thousand
Expected Revenue
$1.20 million
Beat/Miss
Missed by -$974.00 thousand
YoY Revenue Growth
N/A

Conference Call Resources

Catheter Precision Q3 2025 Earnings FAQ

Catheter Precision (NYSEAMERICAN:VTAK) reported earnings of -$17.00 per share for Q3 2025, beating the consensus estimate of -$266.00. The report was announced on Thursday, November 13, 2025.

Catheter Precision reported revenue of $226 thousand for Q3 2025, against a consensus estimate of $1.20 million.

Catheter Precision Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Catheter Precision Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Catheter Precision? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Catheter Precision and other key companies, straight to your email.

About Catheter Precision

Catheter Precision (NYSEAMERICAN:VTAK) is a medical technology company focused on products for electrophysiology, the specialty concerned with diagnosing and treating abnormal heart rhythms. Its products are designed to support clinicians during procedures involving cardiac arrhythmias.

The company’s VIVO system uses patient-specific imaging and electrical data to create a three-dimensional view of the heart and help clinicians locate the source of ventricular arrhythmias before ablation procedures. Catheter Precision also offers LockeT, a device intended to assist with closure of femoral venous access sites after procedures.

Catheter Precision’s product portfolio reflects its focus on tools for planning and supporting electrophysiology procedures. Its shares trade on the NYSE American under the symbol VTAK.

View Catheter Precision Profile